Sign In
Buy VCYT
$48.69
+0.89 (+1.86%)
At Close: Jun 03, 2026
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
09:00am, Friday, 15'th May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BladderCancer--Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer.
Veracyte Inc (VCYT) Shares Fall 3.3% -- What GF Score of 82 Tells Investors
08:19pm, Wednesday, 13'th May 2026
On May 13, 2026, Veracyte Inc (VCYT) shares fell 3.3%, bringing the current price to $38.26. The stock has experienced a 52-week range of $22.61 to $50.71, show
Why Veracyte Stock Is Skyrocketing Higher This Week
12:51am, Friday, 08'th May 2026
Veracyte grew revenue by 21% in Q1 and saw earnings per share quadruple from last year, as margins ballooned. Sales for the company's main prostate and thyroid cancer-detecting tests continue to grow
Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for Investors
10:31am, Thursday, 07'th May 2026
After reaching an important support level, Veracyte (VCYT) could be a good stock pick from a technical perspective. VCYT surpassed resistance at the 200-day moving average, suggesting a long-term bull
Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript
10:51pm, Tuesday, 05'th May 2026
Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript
Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates
09:36pm, Tuesday, 05'th May 2026
Veracyte (VCYT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.31 per share a year ago.
Veracyte Announces First Quarter 2026 Financial Results
04:05pm, Tuesday, 05'th May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2026. “We h
Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a Bet
10:55am, Tuesday, 05'th May 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 39.2% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the posit
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #AUA26--Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
Veracyte (VCYT) Recently Broke Out Above the 50-Day Moving Average
10:31am, Monday, 27'th Apr 2026
Veracyte (VCYT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VCYT broke out above the 50-day moving average, suggesting a
AEGON ASSET MANAGEMENT UK Plc Has $20.60 Million Position in Veracyte, Inc. $VCYT
03:10am, Sunday, 26'th Apr 2026
AEGON ASSET MANAGEMENT UK Plc lifted its holdings in shares of Veracyte, Inc. (NASDAQ: VCYT) by 19.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Se
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
04:05pm, Tuesday, 14'th Apr 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 aft
Comparing Advanced Biomedical Technologies (OTCMKTS:ABMT) and Veracyte (NASDAQ:VCYT)
02:21am, Monday, 06'th Apr 2026
Veracyte (NASDAQ: VCYT - Get Free Report) and Advanced Biomedical Technologies (OTCMKTS:ABMT - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two
Is Veracyte Stock the Right Pick for Your Portfolio Now?
09:27am, Tuesday, 31'st Mar 2026
VCYT rides on Afirma and Decipher growth with strong earnings beat and liquidity, but macro pressures and rising competition cloud its near-term outlook.
Veracyte (VCYT) Down 15.4% Since Last Earnings Report: Can It Rebound?
12:36pm, Friday, 27'th Mar 2026
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
